-+ 0.00%
-+ 0.00%
-+ 0.00%

Cellectar Biosciences Q3 EPS $(0.46) Beats $(0.56) Estimate

Benzinga·11/10/2026 12:01:53
Listen to the news
Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.56) by 17.86 percent. This is a 67.38 percent increase over losses of $(1.41) per share from the same period last year.